tbuckley/cabot-search huggingface dataset:
AB0694 Hepatocyte Growth Factor is Associated with Osteoproliferation in Male as Patients
Authors: E. Klingberg, M. Nurkkala, H. Carlsten, H. Forsblad-d'Elia
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Ankylosing spondylitis (AS) is characterized by osteoproliferation, which can be seen as an enhanced reparative response to inflammation, mechanical stress or micro-damage. Male sex is a risk factor for the disease and for the osteoproliferation. Hepatocyte growth factor (HGF), initially known as a mitogen for hepatocytes, is an important factor for regeneration and repair in many tissues. HGF is produced by osteoblasts, has receptors on osteoblasts and osteoclasts and stimulates both cell types. <h3>Objectives</h3> To compare levels of serum HGF in AS patients with healthy controls and to explore the association with disease activity, osteoproliferation and bone density. <h3>Methods</h3> Serum from AS patients (modified NY-criteria) and healthy controls was analyzed for HGF with ELISA (Quantikine R&amp;DSystems). Disease activity was assessed by BASDAI, ASDAS, ESR and CRP, back-mobility with BASMI, syndesmophyte formation with mSASSS and BMD with DXA of femoral neck. <h3>Results</h3> 204 AS patients (87 women/117 men; age 50±13 years; symptom duration 24±13 years; BASDAI 3.6±2.1; ASDAS-CRP 2.4±0.9) and 80 sex and age-matched controls were included. HGF was significantly higher in the AS patients compared with the controls (1556±452 vs. 1450±527 pg/ml; p=0.024). HGF correlated with age in the male AS patients (r<sub>S</sub>=0.316 p=0.001) but not in the female patients nor in controls of both sexes. In the AS men HGF also correlated with ESR (r<sub>S</sub>=0.380 p&lt;0.001), CRP (r<sub>S</sub>=0.304 p=0.001), BASMI (r<sub>S</sub>=0.323 p&lt;0.001), mSASSS (r<sub>S</sub>=0.302 p=0.001) and BMD of femoral neck (r<sub>S</sub>= -0.211 p=0.022), but in the female patients only with ESR. HGF was significantly higher in male smokers (p=0.005), although there was no age-difference in male smokers and non-smokers. In multiple linear regression age, CRP, and smoking were all independently associated with HGF. <h3>Conclusions</h3> Known risk factors for osteoproliferation in AS were independently associated with serum HGF. HGF could be a negative prognostic biomarker, especially for the male AS patients. Further prospective studies are warranted. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1551
68GA-DOTATATE VASCULAR INFLAMMATION IMAGING PREDICTS HIGH-RISK PLAQUE MORPHOLOGY AND CULPRIT CORONARY LESIONS
Authors: Jason Tarkin, Francis R. Joshi, Nicholas R. Evans, Ashley Groves, Deepa Gopalan, Roie Manavaki, Peter J. Kirkpatrick, Patrick A. Coughlin, John Buscombe, Tim D. Fryer, Martin Bennett, Anthony Davenport, Elizabeth A. Warburton, James Rudd
Journal: Journal of the American College of Cardiology (2016)
Abstract 1624: SIRT1 overexpression in pancreatic adenocarcinomas correlates with shortened patient survival and small molecule inhibition as well as target knockdown of SIRT1 induces growth arrest and apoptosis in pancreatic cancer cells
Authors: Albrecht Stenzinger, Benjamin Göppert, Carsten Kamphues, Bruno Sinn, Markus Bahra, Peter Neuhaus, Wilko Weichert
Journal: Cancer Research (2011)

Abstract Aims: Several lines of evidence indicate that the nuclear enzyme SIRT1 belonging to the class III histone deacetylases is implicated in the initiation and progression of various malignancies. SIRT1 exerts its function by regulating deacetylation of histone and non-histone substrates leading to transcriptional repression of tumor suppressor genes. Recently, SIRT1 gained attraction as druggable target. Since chemotherapeutic treatment options are still very limited in pancreatic cancer we aimed at investigating the potential of SIRT1 in this regard by evaluating the effects of SIRT1 inhibition in vitro and SIRT1 expression in vivo. Methods: Employing immunohistochemistry SIRT1 expression was analyzed in a large cohort of pancreatic ductal adenocarcinomas and subsequently correlated with clinicopathological data and patient survival. Furthermore, we investigated the impact of SIRT1-specific small molecule inhibition and target knock down as well as combinatorial regimens including conventional chemotherapy and small molecule inhibitors directed against the EGFR in pancreatic cancer cell culture models. Using the xCELLigence system, cellular events were measured quantitatively in real time and corroborated by secondary conventional readouts including FACS analysis. Results: We found nuclear SIRT1 expression in 36 (27.9%) of 129 pancreatic carcinomas. SIRT1 expression was significantly higher in poorly differentiated carcinomas (p=0.002). SIRT1 expression was positively correlated with the expression of conventional HDACs suggesting a shared regulation. Strong SIRT1 expression was a significant predictor of poor survival both in univariate (p=0.002) and multivariate (HR 1.65, p=0.045) analysis under inclusion of WHO stage and grade. Small molecule inhibition and target knockdown of SIRT1 lead to a rapid growth arrest and influenced cell viability. This effect was even more pronounced in combinatorial regimens with Gefitinib, but not in combination with Gemcitabine. Conclusions: SIRT1 is shown to be an independent prognostic biomarker for pancreatic adenocarcinomas. Moreover our data suggest that SIRT1 plays an important functional role in pancreatic cancer cell growth, which can be levered out by combinatory small molecule inhibition. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1624. doi:10.1158/1538-7445.AM2011-1624
AB0213 Treatment and outcomes of rheumatoid arthritis patients with hepatitis b
Authors: C.-B. Choi, Y.-K. Sung, S.-K. Cho, D.-H. Yoo, S.-S. Lee, J. Lee, J. Kim, H.-S. Lee, T.-H. Kim, B. Y. Yoon, W.-H. Yoo, J.-Y. Choe, S.-H. Lee, S.-C. Shim, W.-T. Chung, S.-J. Hong, C. K. Lee, E. Koh, J.-B. Jun, S.-Y. Bang, S.-K. Kim, H.-S. Cha, S. Won, S.-C. Bae
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Treatment of rheumatoid arthritis (RA) patients with hepatitis B carries risk for reactivation of hepatitis B and drug-related hepatotoxicity. <h3>Objectives</h3> We investigated the impact of treatment for RA in patients with hepatitis B. <h3>Methods</h3> Patients enrolled in KORONA (Korean Observational Study Network for Arthritis) with 1-year follow up assessment with data on hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (HBcAb) status were included in the analysis. Patient characteristics (age, sex, disease duration, delay in diagnosis, alcohol intake), disease outcome measures (DAS28, fatigue, sleep, HAQ, EQ-5D, radiographic damage, surgery), medications, and adverse events were assessed. Multiple logistic regression was used to analyze the predicting factors for liver function abnormalities. <h3>Results</h3> : A total of 871 patients were assessed. The number of HBsAg-positive and HBcAb-positive patients were 48 (5.5%) and 372 (42.7%), respectively. HBcAb-positive groups were significantly older (56.3 ± 10.8 vs 52.5 ± 9.0 in HBsAg-positive group and 51.3 ± 13.3 in negative group, p&lt;0.01) and had longer disease duration (8.4 ± 7.7 vs 7.7 ± 6.0 in HBsAg-positive group and 7.8 ± 7.2 in negative-group, p=0.46). There was no significant difference in disease outcome measures between the groups, except for significantly increased radiographic damage in HBcAb group (79.6% vs 70.8% in HBsAg-positive group and 72.5% in negative group, p=0.048). Methotrexate and biologics use were significantly lower in HBsAg-positive group, while hydroxychloroquine, sulfasalazine, tacrolimus, and steroids use were significantly higher. HBsAg-positive group had significantly more adverse events (52.1%) compared to HBcAb-positive group (29.3%) and negative group (32.8%). HBsAg-positivity and HBcAb-positivity was not associated with significant increase in liver function abnormalities in the study population in multiple logistic regression analysis (OR (95%CI), 2.2 (0.7-7.4) and 0.8 (0.4-1.7), respectively). <h3>Conclusions</h3> HBsAg-positive patients were more frequently treated with steroids and less with methotrexate, but there was no significant difference in disease outcome. HBsAg-positive patients had more adverse events, but it did not show significant association with developing liver function abnormality. <h3>Acknowledgements</h3> This study is supported by a grant from the Korea Healthcare Technology R&amp;D Project, Ministry of Health and Welfare, Republic of Korea (A102065). <h3>Disclosure of Interest</h3> None Declared
Postmarketing Surveillance of Medical Devices — Filling in the Gaps
Authors: Frederic S. Resnic, Sharon-Lise T. Normand
Journal: New England Journal of Medicine (2012)

Interview with Sharon-Lise Normand on medical device approval and postmarketing surveillance. (00:00)Download Failures of implantable medical devices can carry substantial risk of serious injury, and effective systems for monitoring safety after marketing begins are essential. Several FDA initiatives have been launched to fill the gaps in the passive event-reporting system.
AI-22 * CLINICAL OUTCOME OF BEVACIZUMAB-TREATED PATIENTS WITH RECURRENT MALIGNANT GLIOMAS
Authors: S. Okamoto, M. Nitta, T. Maruyama, Y. Muragaki, T. Saito, S. Ikuta, Y. Okada
Journal: Neuro-Oncology (2014)

INTRODUCTION: Currently, there is no standard therapeutic regimen for recurrent gliomas. Bevacizumab is a recombinant anti-vascular endothelial growth factor (anti-VEGF) antibody. After its approval by the US Food and Drug Administration for recurrent glioblastoma, this drug has been an emerging treatment option for recurrent gliomas; however, the European Medicines Agency has rejected the use of bevacizumab for gliomas. METHODS: We retrospectively analyzed the clinical data of bevacizumab-treated recurrent glioma patients in our department. We included 25 patients (20 men, and 5 women) with recurrent malignant gliomas, aged between 18 and 63 years (median, 39 years), who had undergone bevacizumab-based treatment between February 2009 and September 2012. RESULTS: The median follow-up period was 4 months (range, 1-17 months). The median number of bevacizumab cycles that were administered was 6 (range 1-18 cycles). All of the patients showed radiological reduction of gadorinium -enhanced lesion and 20 (83.3%) patients showed improvement of Karnofsky performance score (KPS) after bevacizumab treatment. The overall response rate was 70%. The median progression-free survival (PFS) for the entire group was 3.3 months and the 6-month PFS (PFS-6m) was 20.8%. The median overall survival (OS) and the 1-year OS (OS-1y) for all patients were 6.7 months and 33.2%, respectively. Patients with primary glioblastoma (pGB) had better OS than those with secondary glioblastoma (sGB); the median OS for pGB and sGB were 7.6, and 4.1 months, respectively (P = 0.06). CONCLUSION: Anti-angiogenic therapy using bevacizumab for recurrent gliomas appears to improve patients the activity for daily living for a few months. However, this therapy did not improve patient overall survival. Further, this therapy cannot be recommended for patients with sGB from grade II and grade III gliomas.
An Unusual, Nonhealing Ulcer on the Forearm
Authors: Alan D. Tice
Journal: New England Journal of Medicine (2002)

To the Editor: A 32-year-old woman presented to the emergency department because of a large and painful ulcer over the ulnar aspect of her left forearm. She said it had been present for more than a year but had become increasingly painful during the previous few weeks. On further questioning, she admitted to using it to inject heroin. The border of this chronic ulcer was very vascular, and injections into it produced nearly the same effect as the intravenous route. The ulcer shown in Figure 1 was approximately 5 cm by 9 cm with a relatively clean surface and prominent vascular granulation . . .
Collagenase in the Lower Respiratory Tract of Patients with Idiopathic Pulmonary Fibrosis
Authors: James E. Gadek, Jeffrey A. Kelman, Gerald Fells, Steven E. Weinberger, Alan L. Horwitz, Herbert Y. Reynolds, Jack D. Fulmer, Ronald G. Crystal
Journal: New England Journal of Medicine (1979)

To test the hypothesis that idiopathic pulmonary fibrosis (IPF) is mediated through collagenase present in the lower respiratory tract, we used the fiberoptic bronchoscope to obtain fluid from the lower respiratory tract of 24 patients with IPF, 18 controls and nine patients with sarcoidosis. The fluid was analyzed for a variety of enzymes, including collagenase. Fifteen of 21 patients with IPF showed collagenase activity, whereas normal controls and patients with sarcoidosis showed none (P<0.001, for all comparisons). In two patients with IPF who were re-evaluated after eight to 24 months, the collagenase activity was persistent. Fluid from patients with IPF also contained elevated levels of a nonspecific neutral protease (P<0.01 compared with controls), but there was no elastase activity in fluid from patients with IPF or from controls. The collagenase found in lavage fluid in IPF cleaved lung collagen into collagenase-specific TCA and TCB fragments. We conclude that in IPF the collagen of the lung is subjected to sustained lysis, followed by disordered resynthesis, and that the presence of active collagenase in the lower respiratory tract is a specific feature of the alveolitis associated with this disease. (N Engl J Med 301:737–742, 1979)
Abstract 3012: Development of a microRNA signature for risk of progression in renal cell carcinoma
Authors: Gowrishankar Banumathy, Ilsiya Ibragimova, Tahseen Al-Saleem, Robert G. Uzzo, Paul Cairns
Journal: Cancer Research (2010)

Abstract The incidence of asymptomatic pathologically localized renal cell carcinoma (RCC) has shown the greatest increase in recent decades. Despite the finding of organ-confined (pT1 or T2) disease at the time of nephrectomy, a subset of patients will have local recurrence or distant metastasis after nephrectomy. Most solid neoplasms are now thought to accumulate a series of genetic and epigenetic changes as they progress through well-defined clinical and histopathological changes. The association of particular molecular markers with progression and outcome of disease means that the status of certain markers can be used to identify the presence of disease and its likelihood for progression. To identify an epigenetic signature that may predict recurrence in patients with organ-confined RCC, we examined RNA hybridized to the Agilent microRNA (miRNA) array from a large number (&amp;gt;100) of RCC patients with extensive clinicopathological annotation. The potential of miRNAs as biomarkers for risk of progression and early detection of recurrent RCC has not yet been studied. Since approximately 90% of metastatic RCC is of clear cell histology, we examined only this histological cell type. The cell type and grade of the RCC was re-reviewed blind by a single pathologist. miRNA expression signatures were established from a series of low grade (I-II), low stage (pT1-2) clear cell RCC with no evidence of disease after nephrectomy for at least 5 years; a series of high grade, high stage (pT3-4), clear cell RCC; and a series of low grade and low stage clear cell RCC that progressed. The expression of particular miRNAs was validated by qRT-PCR. In the growing number of patients who have undergone surgical resection for organ-confined RCC, the near term goal would be to identify those that should be followed more closely and a future goal, depending upon results of ongoing therapeutic trials, to be directed to adjuvant therapy. There would also be cost benefits in potentially following those RCC patients with lowest risk of progression less frequently. MiRNA signatures obtained by our study will address the clinical question whether risk of progression could be defined in patients with organ-confined RCC at initial surgery. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3012.
Who cares for young carers?
Authors: S Jenkins, C Wingate
Journal: BMJ (1994)

How much do we know of young carers - that is, children under 18 who provide primary care for sick, disabled, or elderly relatives in the home, usually their own parents?1 Meredith suggested that health professionals have failed to identify such children and have shown interest in them only when the possibility of psychological or physical disorders has been raised.2

Small studies have suggested that there are at least 10 000 young carers in Britain.3,4 Recent research has, however, rejected the usefulness of such data, concentrating instead on the qualitative impact that caring may have on a child's health, psychosocial development, and opportunities.*RF 5-7*

A substantial obstacle to addressing the needs and concerns of young carers has been a lack of awareness of their existence. Providers of services - whether health, education, or social services - have consistently failed to identify young carers. As one young carer said, “You can't picture a child picking up an adult, getting them on to the stair lift, taking them up, bathing them. If you can't picture it, it doesn't happen.”8

Bilsborrow refers …
OPTICAL COHERENCE TOMOGRAPHY ANALYSIS OF THE SOS XIENCE V STUDY: THE USE OF THE EVEROLIMUS-ELUTING STENT IN SAPHENOUS VEIN GRAFT LESIONS
Authors: Aristotelis Charalampos Papayannis, Tesfaldet Michael, Dinara Yangirova, Abdul&ndash;rahman Abdel&ndash;Karim, Julia Kohlhaas, Arif Mahmood, Tayo Addo, Donald Haagen, Lorenza Makke, Michele Roesle, Bavana Rangan, Subhash Banerjee, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2012)
PERCUTANEOUS MITRAL VALVE DIRECT ANNULOPLASTY WITH A “SURGICAL-LIKE” RING: RESULTS FROM MULTICENTRE FIRST-IN-MAN FEASIBILITY TRIAL
Authors: Francesco Maisano, Karl-Heinz Kuck, Antonio Colombo, Georg Nickenig, Stephan Baldus, Christian Frerker, David Messika-Zeitoun, Alec Vahanian
Journal: Journal of the American College of Cardiology (2015)
A minimally invasive technique utilizing percutaneous and endoscopic rendezvous for successful treatment of a proximal bile leak following partial hepatectomy
Authors: Payal Saxena, Adam Jeffers, Sally Mitchell, Timothy Pawlik, Joanna Law, Vivek Kumbhari, Mouen Khashab, Vikesh Singh
Journal: Endoscopy (2014)

A 43-year-old woman presented with a grade B [1] bile leak after right hepatectomy for metastatic colon cancer. She developed subhepatic bilomas which were managed with percutaneous drains. Endoscopic retrograde cholangiography (ERC) demonstrated a high-grade bile leak secondary to a large defect in the left hepatic duct, possibly due to complete dehiscence of the staple line of the right hepatic bile duct. Despite placement of a fully covered self-expandable metallic stent (SEMS), the bile leak persisted. Percutaneous transhepatic biliary drainage (PTBD) was attempted. The left hepatic duct was accessed in an antegrade fashion; however, the guidewire repeatedly entered the subhepatic space and could not be directed into the common bile duct. Simultaneous ERC and PTBD were performed. The leak ([Fig. 1]) and discontinuity between the left hepatic duct and common bile duct was redemonstrated at ERC. A guidewire was advanced in a retrograde manner to the area just distal to the leak ([Fig. 2]). A 15-mm snare (Amplatz GooseNeck, Covidien, Plymouth, Minnesota, USA) was advanced in an antegrade manner across the left hepatic duct defect to capture the wire ([Fig. 3]) and pulled externally to secure biliary access. A percutaneous biliary drainage catheter was directed over the guidewire, through the SEMS, into the distal duodenum using endoscopic guidewire traction ([Fig. 4]). The drain was customized with additional side holes which remained within the intrahepatic biliary tree but not in the region of the ductal defect ([Fig. 5]). At 6-month follow-up, the subhepatic collections had resolved on imaging.
Concussions in National Hockey League (NHL) players: 5-year video analysis
Authors: Michael Hutchison, Paul Comper
Journal: British Journal of Sports Medicine (2013)

Objectives To understand, through video analysis, how playing characteristics and mechanism of injury contribute to concussions in the National Hockey League (NHL). Setting National Hockey League. Design Prospective case series of concussions over a 5 year period of regular season NHL games (2006–2011). Subjects Digital video images of 341 diagnosed concussions of NHL players. Outcome Measures Concussions were analysed and coded using the Heads Up Checklist (HUC). The HUC consists of 17 groups of factors, categorised within three main domains: (1) Physical Event, (2) Equipment, and (3) Game Situation. In addition, player characteristics (ie, height, weight, and position) were also captured. Results During the first 4 years of study period, a common injury mechanism characterised by player-to-player contact and resulting in contact to the head by the shoulder, elbow, or gloves, was identified. Several important characteristics were also discerned: (i) Contact often to the lateral aspect of the head; (ii) Player was often not in possession of the puck; and (iii) No penalty was called on the play. For the 2010–11 season, despite the absolute number of concussions remaining similar to previous years of study, the mechanism of direct contact to the head accounted for fewer concussions observed. Conclusions Based on the results from this longitudinal study, it appears that majority of concussions are a result of direct contact to the head. Initiatives to reduce eliminate specific behaviours appears to have had an impact as fewer direct contacts to the head were identified. Competing interests One of the authors (PC) is a paid consultant for the National Hockey League Players' Association (NHLPA).
Impact of Sublingual and Oral Immunotherapy for Peanut Allergy on Blood Dendritic Cells
Authors: Mark Gorelik, Satya Narisety, Kristin Chichester, Anthony Guerrerio, Anja P. Bieneman, Corinne Keet, Robert G. Hamilton, Robert A. Wood, John T. Schroeder, Pamela Frischmeyer Guerrerio
Journal: Journal of Allergy and Clinical Immunology (2015)
Case 26-1968
Authors: Robert H. Schapiro, Benjamin Castleman
Journal: New England Journal of Medicine (1968)

Presentation of CaseA sixty-four-year-old man was admitted to the hospital because of jaundice.He had been well until five weeks previously, when abdominal bloating with frequent eructation developed, accompanied by darkening of the urine and lightening of the stool color. There had been no abdominal pain, intolerance of fatty food, chills or fever. He had taken no medications other than antacids and had had no recent injections. One week after the onset of symptoms physical examination was negative; the bilirubin was 1.8 mg per 100 ml, the glutamic oxalacetic transaminase (SGOT) 133 units, and the alkaline phosphatase 18 Bodansky . . .